Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL427126 | 0.99 | PDE2A (0.34) | PDE2AIDH1CETPCYP11B2CYP11B1 | |
| SCHEMBL425368 | 0.73 | KDM4E (0.39) | PDE2AIDH1CYP11B2CYP11B1 | |
| SCHEMBL24212345 | 0.67 | GLA (0.41) | PDE2A | |
| SCHEMBL24212647 | 0.67 | AKR1C3 (0.43) | PDE2ACETP | |
| SCHEMBL24910274 | 0.66 | PDE2A (0.45) | PDE2ACYP11B2CYP11B1 | |
| SCHEMBL12868145 | 0.65 | PDE2A (0.46) | PDE2A | |
| SCHEMBL84521 | 0.65 | PDE2A (0.70) | PDE2A | |
| SCHEMBL8074637 | 0.65 | PDE2A (0.55) | PDE2ACETP | |
| SCHEMBL24910427 | 0.65 | PDE2A (0.41) | PDE2ACETP | |
| SCHEMBL12889906 | 0.65 | PDE2A (0.53) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404673-B2 | Carbocyclic GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022042-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | KOLCZEWSKI SABINE (DE) | 2012-01-26 | — | — | US | disclosed |
| US-8080541-B2 | Carbocyclic GlyT-1 receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | PDE2A 2490/4885IDH1 1699/4885CETP 1676/4885 |
| US-20120022042-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | PDE2A 2490/4885IDH1 1699/4885CETP 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.